hTERT and BIRC5 gene promoters for cancer gene therapy: A comparative study

Shepelev,Mikhail  V.; Kopantzev,Eugene  P.; Vinogradova,Tatiana  V.; Sverdlov,Eugene  D.; Korobko,Igor V.

doi:10.3892/ol.2016.4718

hTERT and BIRC5 gene promoters for cancer gene therapy: A comparative study

Authors:
- Mikhail V. Shepelev
- Eugene P. Kopantzev
- Tatiana V. Vinogradova
- Eugene D. Sverdlov
- Igor V. Korobko
View Affiliations

Affiliations: Institute of Gene Biology, Russian Academy of Sciences, Moscow 119334, Russia, Shemyakin‑Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow 117997, Russia
Published online on: June 15, 2016 https://doi.org/10.3892/ol.2016.4718
Pages: 1204-1210

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Human telomerase reverse transcriptase (hTERT) and survivin (BIRC5) gene promoters are frequently used for transcriptional targeting of tumor cells, yet there is no comprehensive comparative analysis allowing rational choice of a promoter for a particular therapy. In the current study, the transcriptional activity of hTERT, human BIRC5 and mouse Birc5 promoters and their modifications were compared in 10 human cancer cell lines using the luciferase reporter gene activity assay. The results revealed that BIRC5‑ and hTERT‑based promoters had strikingly different cell specificities with comparable activities in only 40% of cell lines. Importantly, relative hTERT and BIRC5 transcript abundance cannot be used to predict the most potent promoter. Among the hTERT‑based promoters that were assessed, modification with the minimal cytomegalovirus promoter generally resulted in the most potent activity. Mouse Birc5 and modified human BIRC5 promoters were superior to the unmodified human survivin promoter; however, their tumor specificities must be investigated further. In summary, the present results emphasize the desirability for construction of more universal tumor-specific promoters to efficiently target a wide spectrum of tumor cells.

View Figures

View References

1	Saukkonen K and Hemminki A: Tissue-specific promoters for cancer gene therapy. Expert Opin Biol Ther. 4:683–696. 2004. View Article : Google Scholar : PubMed/NCBI
2	Dorer DE and Nettelbeck DM: Targeting cancer by transcriptional control in cancer gene therapy and viral oncolysis. Adv Drug Deliv Rev. 61:554–571. 2009. View Article : Google Scholar : PubMed/NCBI
3	Lee M: Hypoxia targeting gene expression for breast cancer gene therapy. Adv Drug Deliv Rev. 61:842–849. 2009. View Article : Google Scholar : PubMed/NCBI
4	Zhu ZB, Makhija SK, Lu B, Wang M, Kaliberova L, Liu B, Rivera AA, Nettelbeck DM, Mahasreshti PJ, Leath CA, et al: Transcriptional targeting of tumors with a novel tumor-specific survivin promoter. Cancer Gene Ther. 11:256–262. 2004. View Article : Google Scholar : PubMed/NCBI
5	Qiao J, Doubrovin M, Sauter BV, Huang Y, Guo ZS, Balatoni J, Akhurst T, Blasberg RG, Tjuvajev JG, Chen SH and Woo SL: Tumor-specific transcriptional targeting of suicide gene therapy. Gene Ther. 9:168–175. 2002. View Article : Google Scholar : PubMed/NCBI
6	Hardcastle J, Kurozumi K, Chiocca EA and Kaur B: Oncolytic viruses driven by tumor-specific promoters. Curr Cancer Drug Targets. 7:181–189. 2007. View Article : Google Scholar : PubMed/NCBI
7	Glinka EM, Edelweiss EF and Deyev SM: Eukaryotic expression vectors and immunoconjugates for cancer therapy. Biochemistry (Mosc). 71:597–606. 2006. View Article : Google Scholar : PubMed/NCBI
8	Sadeghi H and Hitt MM: Transcriptionally targeted adenovirus vectors. Curr Gene Ther. 5:411–427. 2005. View Article : Google Scholar : PubMed/NCBI
9	Ambrosini G, Adida C and Altieri DC: A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med. 3:917–921. 1997. View Article : Google Scholar : PubMed/NCBI
10	Altieri DC: Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer. 8:61–70. 2008. View Article : Google Scholar : PubMed/NCBI
11	Andersen MH, Svane IM, Becker JC and Straten PT: The universal character of the tumor-associated antigen survivin. Clin Cancer Res. 13:5991–5994. 2007. View Article : Google Scholar : PubMed/NCBI
12	Bao R, Connolly DC, Murphy M, Green J, Weinstein JK, Pisarcik DA and Hamilton TC: Activation of cancer-specific gene expression by the survivin promoter. J Natl Cancer Inst. 94:522–528. 2002. View Article : Google Scholar : PubMed/NCBI
13	Chen JS, Liu JC, Shen L, Rau KM, Kuo HP, Li YM, Shi D, Lee YC, Chang KJ and Hung MC: Cancer-specific activation of the survivin promoter and its potential use in gene therapy. Cancer Gene Ther. 11:740–747. 2004. View Article : Google Scholar : PubMed/NCBI
14	Fukuda S and Pelus LM: Survivin, a cancer target with an emerging role in normal adult tissues. Mol Cancer Ther. 5:1087–1098. 2006. View Article : Google Scholar : PubMed/NCBI
15	Li F and Altieri DC: Transcriptional analysis of human survivin gene expression. Biochem J. 344:305–311. 1999. View Article : Google Scholar : PubMed/NCBI
16	Vaĭshlia NA, Zinov'eva MV, Sass AV, Kopantsev EP, Vinogradova TV and Sverdlov ED: Increase of BIRC5 gene expression in non-small cell lung cancer and esophageal squamous cell carcinoma does not correlate with expression of genes SMAC/DIABLO and PML encoding its inhibitors. Mol Biol (Mosk). 42:652–661. 2008.PubMed/NCBI
17	Van Houdt WJ, Haviv YS, Lu B, Wang M, Rivera AA, Ulasov IV, Lamfers ML, Rein D, Lesniak MS, Siegal GP, et al: The human survivin promoter: A novel transcriptional targeting strategy for treatment of glioma. J Neurosurg. 104:583–592. 2006. View Article : Google Scholar : PubMed/NCBI
18	Lu B, Makhija SK, Nettelbeck DM, Rivera AA, Wang M, Komarova S, Zhou F, Yamamoto M, Haisma HJ, Alvarez RD, et al: Evaluation of tumor-specific promoter activities in melanoma. Gene Ther. 12:330–338. 2005. View Article : Google Scholar : PubMed/NCBI
19	Rein DT, Breidenbach M, Nettelbeck DM, Kawakami Y, Siegal GP, Huh WK, Wang M, Hemminki A, Bauerschmitz GJ, Yamamoto M, et al: Evaluation of tissue-specific promoters in carcinomas of the cervix uteri. J Gene Med. 6:1281–1289. 2004. View Article : Google Scholar : PubMed/NCBI
20	Konopka K, Spain C, Yen A, Overlid N, Gebremedhin S and Düzgüneş N: Correlation between the levels of survivin and survivin promoter-driven gene expression in cancer and non-cancer cells. Cell Mol Biol Lett. 14:70–89. 2009. View Article : Google Scholar : PubMed/NCBI
21	Mityaev MV, Kopantzev EP, Buzdin AA, Vinogradova TV and Sverdlov ED: Enhancer element potentially involved in human survivin gene promoter regulation in lung cancer cell lines. Biochemistry (Mosc). 75:182–191. 2010. View Article : Google Scholar : PubMed/NCBI
22	Bett AJ, Prevec L and Graham FL: Packaging capacity and stability of human adenovirus type 5 vectors. J Virol. 67:5911–5921. 1993.PubMed/NCBI
23	Li F and Altieri DC: The cancer antiapoptosis mouse survivin gene: Characterization of locus and transcriptional requirements of basal and cell cycle-dependent expression. Cancer Res. 59:3143–3151. 1999.PubMed/NCBI
24	Xia F and Altieri DC: Mitosis-independent survivin gene expression in vivo and regulation by p53. Cancer Res. 66:3392–3395. 2006. View Article : Google Scholar : PubMed/NCBI
25	Kyo S, Takakura M, Fujiwara T and Inoue M: Understanding and exploiting hTERT promoter regulation for diagnosis and treatment of human cancers. Cancer Sci. 99:1528–1538. 2008. View Article : Google Scholar : PubMed/NCBI
26	Gu J and Fang B: Telomerase promoter-driven cancer gene therapy. Cancer Biol Ther. 2(4 Suppl 1): S64–S70. 2003.PubMed/NCBI
27	Janknecht R: On the road to immortality: HTERT upregulation in cancer cells. FEBS Lett. 564:9–13. 2004. View Article : Google Scholar : PubMed/NCBI
28	Horikawa I, Cable PL, Afshari C and Barrett JC: Cloning and characterization of the promoter region of human telomerase reverse transcriptase gene. Cancer Res. 59:826–830. 1999.PubMed/NCBI
29	Takakura M, Kyo S, Kanaya T, Hirano H, Takeda J, Yutsudo M and Inoue M: Cloning of human telomerase catalytic subunit (hTERT) gene promoter and identification of proximal core promoter sequences essential for transcriptional activation in immortalized and cancer cells. Cancer Res. 59:551–557. 1999.PubMed/NCBI
30	Horikawa I and Barrett JC: Transcriptional regulation of the telomerase hTERT gene as a target for cellular and viral oncogenic mechanisms. Carcinogenesis. 24:1167–1176. 2003. View Article : Google Scholar : PubMed/NCBI
31	Poole JC, Andrews LG and Tollefsbol TO: Activity, function, and gene regulation of the catalytic subunit of telomerase (hTERT). Gene. 269:1–12. 2001. View Article : Google Scholar : PubMed/NCBI
32	Wick M, Zubov D and Hagen G: Genomic organization and promoter characterization of the gene encoding the human telomerase reverse transcriptase (hTERT). Gene. 232:97–106. 1999. View Article : Google Scholar : PubMed/NCBI
33	Cong YS, Wen J and Bacchetti S: The human telomerase catalytic subunit hTERT: Organization of the gene and characterization of the promoter. Hum Mol Genet. 8:137–142. 1999. View Article : Google Scholar : PubMed/NCBI
34	Davis JJ, Wang L, Dong F, Zhang L, Guo W, Teraishi F, Xu K, Ji L and Fang B: Oncolysis and suppression of tumor growth by a GFP-expressing oncolytic adenovirus controlled by an hTERT and CMV hybrid promoter. Cancer Gene Ther. 13:720–723. 2006. View Article : Google Scholar : PubMed/NCBI
35	Wirth T, Zender L, Schulte B, Mundt B, Plentz R, Rudolph KL, Manns M, Kubicka S and Kühnel F: A telomerase-dependent conditionally replicating adenovirus for selective treatment of cancer. Cancer Res. 63:3181–3188. 2003.PubMed/NCBI
36	Mikhaĭlova IN, Lukashina MI, Baryshnikov AIu, Morozova LF, Burova OS, Palkina TN, Kozlov AM, Golubeva VA, Cheremushkin EA, Doroshenko MB, et al: Melanoma cell lines as the basis for antitumor vaccine preparation. Vestn Ross Akad Med Nauk. 37–40. 2005.